NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Rivian (RIVN) Valuation Check as Major Van Recall Collides With R2 Plans and Volkswagen Partnership

Rivian Automotive (RIVN) is back in the spotlight after announcing a recall of nearly 35,000 electric delivery vans in the U.S. over a seat belt pretensioner cable issue, raising fresh questions about execution and long term upside. See our latest analysis for Rivian Automotive. Even with the recall noise, investors have been leaning back toward the story. A roughly 35% year to date share price return and a 38% one year total shareholder return suggest momentum is rebuilding rather than...
NYSE:QTWO
NYSE:QTWOSoftware

How Investors May Respond To Q2 Holdings (QTWO) Slowing ARR Growth And Persistent Margin Pressures

In the recent quarter, Q2 Holdings reported annual recurring revenue of US$888.4 million, growing 11.3% year on year, while analysts now project revenue growth of 10.7% over the next 12 months amid intensifying competition. An important takeaway is that Q2’s average gross margin of 53.4% over the last year remains relatively low for a software company, suggesting structurally higher infrastructure costs and ongoing profitability pressures. We’ll now examine how slowing annual recurring...
NasdaqGS:GTLB
NasdaqGS:GTLBSoftware

GitLab (GTLB) Valuation Check After Q3 Beat, Softer Outlook and Leadership Changes

GitLab (GTLB) just delivered third quarter numbers that topped expectations, but the stock reaction has been choppy as investors weigh strong subscription growth against a cooler revenue outlook for the coming quarter. See our latest analysis for GitLab. The stock tells a more cautious story than the business does. The year-to-date share price return is down about 33 percent and the 1-year total shareholder return is off roughly 44 percent. This suggests momentum has clearly faded as...
NYSE:POST
NYSE:POSTFood

Is Post Holdings (POST) Trading Near-Term Interest Costs For Longer-Term Capital Flexibility?

Post Holdings has recently completed a private offering of US$1.30 billion 6.50% senior unsecured notes due 2036 and used the proceeds to fund the planned redemption of US$1,235.0 million 5.50% senior notes due 2029 at 101.833% of principal, plus accrued interest. This refinancing extends Post's debt maturity profile while increasing its interest burden, and sits alongside a new US$500 million, two-year share repurchase authorization that could reshape its capital structure. We’ll now...
NYSE:WT
NYSE:WTCapital Markets

WisdomTree (WT) Valuation Check After Launch of Blockchain-Enabled Equity Premium Income Digital Fund

WisdomTree (WT) just rolled out its Equity Premium Income Digital Fund, pairing a traditional put write strategy with blockchain based tokenization, and that mix is exactly what has investors rechecking their assumptions on the stock. See our latest analysis for WisdomTree. The launch of the digital premium income fund comes as WisdomTree’s 1 day share price return of 1.86 percent and 7 day share price return of 4.08 percent hint that sentiment is stabilising after a tougher 90 day stretch...
NasdaqGS:ADBE
NasdaqGS:ADBESoftware

Assessing Adobe (ADBE) Valuation After Buyback-Driven Rebound and Growing AI Growth Expectations

Adobe (ADBE) popped about 6% in afternoon trading after management emphasized its hefty share repurchase program, lifting investor confidence heading into the upcoming fourth quarter earnings report. See our latest analysis for Adobe. The latest 1 day share price return of 5.33 percent, taking Adobe to 346.26 dollars, stands in stark contrast to its 21.48 percent year to date share price decline and 37.38 percent 1 year total shareholder return. This suggests that today’s optimism around...
NasdaqGS:LITE
NasdaqGS:LITECommunications

Lumentum (LITE): Assessing Valuation After AI-Driven Earnings Surge and Bullish Options Momentum

Lumentum Holdings (LITE) just delivered a standout quarter powered by AI infrastructure demand, and options markets quickly responded, with bullish call activity and Power Inflow signals hinting at shifting expectations for the stock. See our latest analysis for Lumentum Holdings. That excitement is showing up clearly in the tape, with a roughly 42% 1 month share price return and a powerful 256.97% 1 year total shareholder return, signaling momentum that traders are now trying to front run...
NasdaqGS:NEOG
NasdaqGS:NEOGMedical Equipment

What Neogen (NEOG)'s Portfolio Simplification and Divestitures Strategy Means For Shareholders

Neogen recently moved to simplify its portfolio and accelerate deleveraging by divesting lower-quality businesses tied to its 2022 merger with 3M’s Food Safety division, while working through the final stages of integration. This shift, driven by new leadership and a tighter focus on higher-growth areas such as bovine-related products, highlights a push to improve operational efficiency and concentrate resources on the company’s strongest food and animal safety franchises. We’ll now examine...
NasdaqGS:AZTA
NasdaqGS:AZTALife Sciences

How Investors May Respond To Azenta (AZTA) Delaying Its 10-K Filing And Financial Disclosures

On 2 December 2025, Azenta, Inc. disclosed that it would miss the SEC deadline for filing its next Form 10-K annual report, signaling a delay in its formal financial disclosures. This kind of filing delay can heighten investor scrutiny of the company’s financial reporting processes, internal controls, and overall transparency at a sensitive time for life sciences businesses. We’ll now explore how Azenta’s delayed 10-K filing may affect the previously outlined investment narrative,...
NasdaqGS:ROKU
NasdaqGS:ROKUEntertainment

Roku (ROKU) Valuation Check After ARK Invest and Insider Stock Sales Shake Investor Sentiment

Roku (ROKU) slipped after Cathie Wood's ARK Invest trimmed its position for a second straight day, extending a string of high profile stock sales that now includes earlier disposals by Roku's CEO. See our latest analysis for Roku. Even with ARK trimming its stake and a recent software glitch weighing on sentiment, Roku’s share price still shows a solid year to date rebound. It has a 34.4% year to date share price return and a 3 year total shareholder return of 93.5%, suggesting longer term...
NasdaqGS:ALGM
NasdaqGS:ALGMSemiconductor

Assessing Allegro MicroSystems (ALGM) Valuation After Bullish Analyst Consensus Fuels Recent Share Price Uptick

Allegro MicroSystems (ALGM) rose about 4% after Wall Street largely lined up on the bullish side, with a clear majority of analysts signaling confidence in the chip designer’s longer term growth story. See our latest analysis for Allegro MicroSystems. The latest uptick builds on a solid year to date, with a roughly 28% year to date share price return and a 1 year total shareholder return near 38% pointing to strengthening momentum as confidence in Allegro’s growth story improves. If this kind...
NasdaqGS:SAIC
NasdaqGS:SAICProfessional Services

Science Applications International (SAIC) Is Up 16.7% After Boosting 2026 Outlook, Buybacks, And Dividend

In early December 2025, Science Applications International Corporation reported Q3 results with revenue of US$1.87 billion and net income of US$78 million, raised its full-year 2026 revenue guidance, completed a US$407.16 million buyback covering 7.83% of shares, and declared a quarterly dividend of US$0.37 per share payable in January 2026. Amid softer year-on-year sales, SAIC’s improved earnings guidance, meaningful share repurchases, growing defense contract wins, and commitment to...
NasdaqGS:CPB
NasdaqGS:CPBFood

Assessing Campbell Soup’s (CPB) Valuation After a Prolonged Share Price Slide

Campbell's (CPB) has been a frustrating hold lately, with the stock drifting lower despite steady revenue and improving profits. That disconnect between lukewarm share performance and underlying results is what makes the setup interesting. See our latest analysis for Campbell's. The share price has slipped to about $29.60, and that weak 90 day share price return of around negative 13 percent and three year total shareholder return near negative 41 percent suggest momentum is still fading...
NYSE:PAYC
NYSE:PAYCProfessional Services

Paycom Software (PAYC): Reassessing Valuation After Recent Share Price Weakness

Paycom Software (PAYC) has been under pressure lately, with shares down around 10% over the past month and roughly 26% in the past 3 months, prompting fresh questions about its valuation. See our latest analysis for Paycom Software. Zooming out, the stock’s recent slide sits on top of a much tougher backdrop, with a negative 1 year total shareholder return and a steep 3 year total shareholder return decline suggesting momentum has been fading despite ongoing revenue and profit growth. If...
NYSE:DFIN
NYSE:DFINCapital Markets

Donnelley Financial Solutions (DFIN) Is Down 6.6% After ActiveDisclosure Retention Slips And Competition Intensifies – Has The Bull Case Changed?

Donnelley Financial Solutions recently reported weakening gross and net retention, with its flagship ActiveDisclosure software showing slower annual recurring revenue growth amid intensifying competition. The fading benefit from earlier regulatory tailwinds and rising pressure from rivals such as Workiva raise fresh questions about DFIN’s ability to shift more of its business to higher-margin software. Next, we’ll consider how deteriorating retention for ActiveDisclosure may alter Donnelley...
NasdaqGS:STLD
NasdaqGS:STLDMetals and Mining

Is Steel Dynamics Still Attractive After Its 2025 Rally and Strong Valuation Signals?

If you are wondering whether Steel Dynamics is still worth buying after its big run, or if the easy money has already been made, you are in the right place to unpack what the market is really pricing in. The stock has cooled slightly over the last 7 days with a -1.6% move, but it is still up 7.2% over the last month, 47.6% year to date, 22.6% over 1 year, 59.4% over 3 years, and 359.0% over 5 years. Recent momentum in Steel Dynamics has been shaped by ongoing optimism around US...
NYSE:WK
NYSE:WKSoftware

Workiva (WK): Evaluating Valuation After Recent Double-Digit Share Price Rebound

Workiva (WK) has quietly put up double digit gains over the past month, even as its year to date return is still in the red. That mix of recent strength and longer term lag sets up an interesting entry point. See our latest analysis for Workiva. With the share price now around $92 and a strong 30 day share price return offsetting a weaker year to date performance, the recent 90 day upswing suggests momentum is quietly rebuilding as investors re rate Workiva's growth story and risk profile. If...
NYSE:OVV
NYSE:OVVOil and Gas

NuVista Acquisition And New Coverage Could Be A Game Changer For Ovintiv (OVV)

In recent days, William Blair began covering Ovintiv Inc. with an Outperform rating, highlighting the company’s completed acquisition of NuVista and its projected 2026 production contribution of 100,000 barrels of oil equivalent per day. The firm also pointed to Ovintiv’s established infrastructure in the Montney and Permian basins and potential asset sales as key levers for delivering shareholder returns via dividends and buybacks. We’ll now assess how William Blair’s upbeat initiation,...
NYSE:IONQ
NYSE:IONQTech

IonQ (IONQ) Is Up 6.9% After 99.99% Fidelity Breakthrough and New Biotech, Defense Deals

In late 2025, IonQ announced a series of developments, including a world-record 99.99% two-qubit gate fidelity, new quantum partnerships in biotech and defense, and an expanded international footprint through leadership appointments such as Dr. Marco Pistoia heading IonQ Italia. Together with its investment in Horizon Quantum Computing’s PIPE financing and its role as core technology partner for CCRM’s quantum-biotech initiatives, IonQ is increasingly positioning itself as a full-stack...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

Sarepta Therapeutics (SRPT): Valuation Check After New ENDEAVOR Dosing Approval and SRP-1003 Pipeline Milestones

Sarepta Therapeutics (SRPT) just cleared two important clinical hurdles, with the FDA greenlighting dosing for Cohort 8 in its ENDEAVOR gene therapy study and fresh progress in its SRP 1003 RNA program for myotonic dystrophy. See our latest analysis for Sarepta Therapeutics. Those twin updates land at a tense moment for Sarepta, with the stock showing a 19.23% 1 month share price return but a steep 82.63% 1 year total shareholder return decline. This suggests sentiment is stabilising from a...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Two-Year Rezdiffra Cirrhosis Data

Earlier this month, Madrigal Pharmaceuticals reported positive two-year Phase 3 data for its Rezdiffra treatment in patients with compensated MASH cirrhosis, while also granting equity inducement awards to 24 new non-executive employees under its 2025 Inducement Plan. The new data strengthened investor focus on Rezdiffra’s potential role in advanced liver disease just as executives continued preset stock sale programs and analysts reiterated confidence in the drug’s commercial...
NYSE:DXC
NYSE:DXCIT

DXC Technology (DXC) Is Up 7.0% After Showcasing Major Cloud Migration Win With ivari

At AWS re:Invent, DXC Technology announced that Canadian life insurer ivari has completed a large-scale migration of about 732,000 policies to the DXC Assure Platform on Amazon Web Services, achieving a 22% reduction in operating costs and supporting four new product launches without business disruption. This go-live showcases DXC’s ability to execute complex, cloud-enabled transformations in insurance, strengthening its position in core policy administration modernization and business...
NasdaqGS:FWRG
NasdaqGS:FWRGHospitality

How Advent’s Major Stake Cut At First Watch (FWRG) Has Changed Its Investment Story

Advent International has already sold 9,400,000 shares of First Watch Restaurant Group, sharply reducing its stake to 5,289,784 shares worth about US$82.73 million as of September 30, 2025. This large secondary sale by a key shareholder comes as analysts continue to highlight First Watch’s growth potential and the company prepares to present at Barclays’ 11th Annual Eat, Sleep, Play, Shop Conference in New York on December 2, 2025. Next, we’ll examine how Advent International’s sizable share...
NYSE:NVST
NYSE:NVSTMedical Equipment

Envista (NVST): Reassessing Valuation as Earnings Improve and Share Price Begins to Recover

Envista Holdings (NVST) has been quietly grinding higher this year, and with shares now around 20 dollars, investors are starting to revisit the story, especially given its improving earnings profile. See our latest analysis for Envista Holdings. That steady climb has come with a few bumps, as shown by a slightly negative 90 day share price return alongside a modestly positive year to date share price return. Yet the 1 year total shareholder return of 1.71 percent suggests momentum is only...